ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Bryant Furlow

Bryant Furlow

Posts by Author

Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for advanced renal cell carcinoma.

Germline genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will test positive for pathogenic gene variants.

In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.

Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia.

Cardiovascular adverse events are more than twice as frequent in carfilzomib arms of randomized controlled trials in multiple myeloma, according to a systematic review and meta-analysis of 24 studies.

Among high-risk multiple myeloma patients, post-ASCT immunization with the Wilms tumor 1 peptide mixture galinpepimut-S is well tolerated and is associated with promising progression-free survival.

Researchers are making much-needed progress in developing treatments for patients with three rare malignancies: recurrent and refractory primary central nervous (CNS) system lymphoma, secondary CNS lymphoma, and primary vitreoretinal lymphoma.

Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials.

A molecular signature for aggressive-variant prostate carcinoma can predict which men with castration-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin.

Adding daratumumab to standard of care is a feasible alternative to autologous stem cell transplantation with standard regimens in multiple myeloma patients.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.